VBI Vaccines has chosen to advance two candidates from its VBI-2900 COVID-19 vaccine program into an adaptive Phase I/II study set to start by year’s end. One is VBI-2901, a trivalent pan-coronavirus vaccine candidate designed to express the Spike proteins of SARS-CoV-2, as well as SARS-CoV-1 and MERS. The other, VBI-2902, is a monovalent vaccine expressing only the SARS-CoV-2 Spike protein . . .
One COVID-19 Shot, Two Approaches
VBI Vaccines CSO discusses company’s pair of prospects vs. the pandemic
VBI Vaccines has chosen to advance two candidates from its VBI-2900 COVID-19 vaccine program into an adaptive Phase I/II study set to start by year’s end. [VBI Vaccines]